argenx’ Vyvgart Hytrulo Bags the US FDA’s Approval for Treating Chronic Inflammatory Demyelinating Polyneuropathy
Shots:
- The US FDA has granted approval to the company’s Vyvgart Hytrulo (QW, 30-to-90 second, SC injection) co-formulated with Enhanze (rHuPH20) for treating chronic inflammatory demyelinating polyneuropathy (CIDP)
- The approval was supported by the data from (ADHERE) trial investigating the safety and efficacy of Vyvgart Hytrulo (SC) vs PBO for treating CIDP adults (n=322)
- The trial depicted improvements in mobility, function and strength among 69% (221/322) of participants and reached its 1EP showing lower relapse risk by 61% with 99% of them joining ADHERE open-label extension study
Ref: Argenx | Image: Argenx
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
